PipelineReview.com3h
Scholar Rock Reports Apitegromab Meets Primary Endpoint in Phase 3 SAPPHIRE Study in Patients with Spinal Muscular Atrophy (SMA)
CAMBRIDGE, MA, USA I October 07, 2024 I Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for ...
PipelineReview.com3h
Hansa Biopharma’s HNSA-5487 Achieved Rapid and Highly Robust IgG Reduction by More Than 95% and Clear Redosing Potential in First-in-Human Trial
LUND, Sweden I October 7, 2024 I Hansa Biopharma AB, ("Hansa" or the "Company") (NASDAQ STOCKHOLM: HNSA), today announced positive results from a 12-month ...
PipelineReview.com3h
Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two phase III trials in MASH for survodutide
October 08, 2024 I Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy ...
PipelineReview.com3h
Vincerx Reports Positive Initial Clinical Data from Ongoing VIP943 Phase 1 Dose-Escalation Study and Provides Pipeline and Corporate Updates
VIP943 demonstrates promising safety and tolerability and achieves two complete responses to date in Phase 1 dose-escalation study, reinforcing the program’s ...
PipelineReview.com3h
New Data Demonstrate Substantial Therapeutic Potential of Capsida’s IV Gene Therapy for Parkinson’s Disease Associated with GBA Mutations
CAP-003 achieved best-in-class GCase increases in NHPs exceeding levels needed for normalizing activity in patients ...
PipelineReview.com3h
FluoGuide A/S submits Clinical Trial Application for phase II trial in head and neck cancer
The CTA submission follows strong clinical topline data for FG001 tested in a proof-of-concept phase II clinical trial in patients with head and neck cancer and is a step on the path to the patients ...
PipelineReview.com3h
Monopar Initiates Clinical Trial of Novel uPAR-Targeted Radiopharmaceutical Therapy in Advanced Cancers
WILMETTE, IL, USA I October 07, 2024 I Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative ...
PipelineReview.com3h
AstraZeneca strengthens its cardiovascular pipeline with agreement for a pre-clinical novel lipid-lowering therapy
LONDON, UK I October 07, 2024 I AstraZeneca has entered into an exclusive license agreement with CSPC Pharmaceutical Group Ltd (CSPC) to advance the ...
PipelineReview.com3h
Ubix Therapeutics Accepted into Johnson & Johnson Innovation – JLABS
SEOUL, South Korea I October 08, 2024 I Ubix Therapeutics, Inc., a clinical-stage biotechnology company dedicated to the discovery and development of ...
PipelineReview.com3h
MediLink Announces Global Clinical Trial Collaboration and Supply Agreement on YL201 Combination Therapy
This open-label, global, multi-center Phase Ib clinical study is designed to evaluate the safety, tolerability, pharmacokinetics, and efficacy of this combination regimen in ES-SCLC patients. Both ...
PipelineReview.com1d
Johnson & Johnson to Discontinue Phase 2 Field Study Evaluating Investigational Antiviral for the Prevention of Dengue
Mosnodenvir (formerly JNJ-1802) was shown to be safe and well tolerated in previous Phase 1 and Phase 2a clinical studies. Results from the Phase 2a human challenge study found that the compound ...
PipelineReview.com2d
TiumBio Announces First Patient Dosed in Phase 2 Clinical Trial of Oral Immuno-Oncology Drug TU2218
BOSTON, MA, USA and SEONGNAM, South Korea I October 4, 2024 I TiumBio Co., Ltd. (Kosdaq: 321550), a clinical-stage biopharmaceutical company focused on ...